Bayer Leverkusen: Success patented by Xabi
A look at our next Champions League opponentsOur Red Bulls are returning to Europe's biggest football stage next week when we ...
Cytokinetics Secures Strategic Licensing Deal with Bayer, Boosting Global Prospects for Aficamten
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price ...
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an ...
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Bayer is now going to conduct Phase 3 clinical trials for obstructive HCM in Japan, while Cytokinetics will expand its ongoing ACACIA-HCM and CEDAR-HCM trials into Japan.
Bayer price target lowered to EUR 30 from EUR 35 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Bayer (BAYRY) to EUR 30 from EUR 35 and keeps an Equal Weight rating on the shares.Don't Miss ...